NASDAQ$NVAX

Novavax Inc · Q1 2026 earnings

Q1 2026 earnings · · Investor relations

Briefing

Novavax reported Q1 2026 total revenue of $139.5M and a net loss of $9.5M, with diluted loss per share of $0.06.

Total revenue fell to $139.5 million from $666.7 million as COVID vaccine product sales declined to $42.2 million while licensing revenue was $97.3 million. Net loss was $9.5 million, or $0.06 per diluted share, versus $518.6 million income a year ago on pandemic-era sales.

  • Total revenue $139.5M (-79% YoY).
  • Product sales $42.2M; licensing $97.3M.
  • Net loss $(9.5)M; diluted EPS $(0.06).
  • R&D $95.5M on next-gen vaccines.

Headline financials

Total Revenue

$140M

Previous: $667M-79.1%
EPS (adj)

-$0.06

Previous: -$1.05+94.3%
Capital Expenditures

-$1.27M

Previous: -$1.22M-4.1%
Net Income

-$9.49M

Previous: $519M-101.8%
Operating Income

-$15.4M

Previous: $516K-3093.1%

Revenue & EPS history

Novavax · Revenue · Quarterly

$140M

Q1 2026-79.1%vs Q1 2025
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Revenue by segment

Novavax · $2.23M total across 1 segment · Q3 2023

  • Product sales
    $2.23M

Forward guidance

Pipeline and partnership milestones drive outlook; no product revenue guide at prior COVID peaks.

Tailwinds

  • Licensing revenue supports base business.
  • Loss modest relative to revenue base.
  • Cost structure adjusting post-COVID.

Headwinds

  • Product revenue down sharply YoY.
  • R&D still elevated.
  • Commercial adoption of updated COVID shots uncertain.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

+2.5%

Avg return

Earnings day

+5.0%

Avg return

5 days after

+11.8%

Avg return

30 days after

36%

23 / 64 earnings

Positive

+193.3%

Q1 2024

Best reaction

-33.2%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+15.6%+17.3%+17.0%
Q4 2025+0.5%-0.4%-11.3%
Q3 2025-3.0%-3.3%-10.1%
Q1 2025+11.6%+4.0%+25.2%
Q4 2024-3.6%+4.9%-4.4%
Q3 2024-13.8%-18.8%+0.1%
Q2 2024+8.3%+13.5%+8.6%
Q1 2024+193.3%+188.6%+306.5%
Q4 2023-17.9%-8.8%-20.6%
Q3 2023-8.2%-8.2%-18.1%
Q2 2023-5.3%-2.1%+21.7%
Q1 2023+20.7%+13.4%+3.2%
Q4 2022-20.9%-11.3%-24.0%
Q3 2022-4.1%+28.9%-10.9%
Q2 2022-33.2%-31.2%-49.2%
Q1 2022-6.0%-9.4%-12.5%
Q4 2021+2.6%-12.1%-8.4%
Q3 2021-18.4%-13.3%-17.8%
Q2 2021-15.2%+2.9%+12.4%
Q1 2021-21.5%-25.2%+19.1%
Q4 2020-10.9%-24.4%-21.6%
Q3 2020-12.4%+7.5%+28.2%
Q2 2020-12.2%-14.0%-46.7%
Q1 2020+112.6%+132.9%+140.0%
Q4 2019-12.8%-35.1%+60.1%
Q3 2019+3.8%-6.3%-1.6%
Q2 2019-8.2%-15.5%+15.5%
Q1 2019-7.8%-21.6%-44.3%
Q4 2018+7.8%+5.9%+3.9%
Q3 2018-3.7%-10.5%+7.3%
Q2 2018+22.5%+13.3%+24.2%
Q1 2018-1.2%+4.3%-1.2%
Q4 2017-4.2%-2.8%-15.3%
Q3 2017+0.9%+0.0%+24.8%
Q2 2017+3.1%+4.2%+22.9%
Q1 2017+14.9%+35.1%+43.2%
Q4 2016+9.4%+6.5%-7.2%
Q3 2016-3.4%-6.9%+0.7%
Q2 2016-9.2%-6.4%-0.3%
Q1 2016-8.9%
Q4 2015-0.2%
Q3 2015-12.2%
Q2 2015+28.3%
Q1 2015+4.4%
Q4 2014-1.9%
Q3 2014-7.2%
Q2 2014-5.0%
Q1 2014-7.1%
Q4 2013-0.8%
Q3 2013+3.2%
Q2 2013-10.8%
Q1 2013-8.9%
Q4 2012-0.5%
Q3 2012-1.8%
Q2 2012+0.5%
Q1 2012-5.7%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011+5.9%
Q1 2011+0.4%
Q4 2010+0.0%
Q3 2010+1.3%
Q2 2010-1.3%
Q1 2010+14.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro